Rong Tai Pharmaceutical Refiles for Hong Kong IPO, Ranked 3rd in China’s Out-of-Hospital Pharma Digital Marketing

NewTimeSpace News: As disclosed by the Hong Kong Stock Exchange, Guangdong Rong Tai Pharmaceutical Co., Ltd. refiled for main board listing on the Hong Kong Stock Exchange on May 22, 2026, with CITIC Securities serving as the sole sponsor.

Rong Tai Pharmaceutical is a leading provider of digital marketing and supply chain services in China’s out-of-hospital pharmaceutical market, engaged in online and offline pharmaceutical retail and wholesale. Per Frost & Sullivan data, by 2025 revenue:3rd-largest digital marketing and supply chain service provider in China’s out-of-hospital pharmaceutical market;1st among participants targeting individual customers.

The company serves over 2,400 domestic and international pharmaceutical companies, including 15 of the world’s top 20 pharma firms and 81 of China’s top 100 pharmaceutical enterprises. It owns and operates 37 online pharmacies across B2C and O2O e-commerce platforms, covering 230,000+ grassroots terminals, partnering with 220 B2C/O2O platforms, and offering 20,000+ SKUs in the out-of-hospital market.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.